Martha Catalina Morales-Alvarez

Martha Catalina Morales-Alvarez

Auto-generated profile, based on publicly available information

Martha Catalina Morales-Alvarez

Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
MMMartha Catalina Morales-Alvarez
Martha Catalina Morales-Alvarez

31 January 2018 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
FTFreddy J. K. Toloza
Freddy J. K. Toloza
JMJose O. Mantilla-Rivas
Jose O. Mantilla-Rivas
MPMaria C. Pérez-Matos
Maria C. Pérez-Matos
MRMaria L. Ricardo-Silgado
Maria L. Ricardo-Silgado
MMMartha C. Morales-Alvarez
Martha C. Morales-Alvarez
CMCarlos O Mendivil
Carlos O Mendivil
Background: Myokines are a group of protein mediators produced by skeletal muscle under stress or physical exertion. Even though their discovery and effects in cell culture and animal models of disease have elicited great enthusiasm, very little is known about their role in human metabolism. We assessed whether plasma concentrations of three known myokines [myonectin, myostatin, and fibroblast-derived growth factor 21 (FGF-21)] would be associated with direct and indirect indicators of insulin resistance (IR) in individuals who did not have a diagnosis of diabetes. Methods: We studied 81 adults of both sexes comprising a wide range of body adiposity and insulin sensitivity. All participants underwent a thorough clinical assessment and a 5-point oral glucose tolerance test with calculation of multiple IR and insulin sensitivity indices. Twenty-one of them additionally underwent a hyperinsulinemic–euglycemic clamp with determination of steady-state whole-body insulin-stimulated glucose disposal (“M”). We compared plasma myokine concentrations across quartiles of IR indices and clinical IR surrogates, and explored the correlation of each myokine with the M-value. Results: Plasma myonectin levels increased monotonically across quartiles of the incremental area under the insulin curve (higher values indicate more IR) (p-trend = 0.021) and decreased monotonically across quartiles of the insulin sensitivity index (ISI – higher values indicate less IR) (p-trend = 0.012). After multivariate adjustment for other relevant determinants of IR (body mass index, age, and sex), the negative association of myonectin with ISI persisted (standardized beta = −0.235, p = 0.023). Myostatin was not associated with any clinical IR indicator or direct IR index measure. In multivariate analyses, FGF-21 showed a trend toward a positive correlation with glucose disposal that did not reach statistical significance (standardized beta = 0.476, p = 0.091). Conclusion: The secretion of myonectin may constitute an attempt at a compensatory mechanism against IR in humans.

4 September 2018 in Transplant International
Verified
Journal Article
Closed access
PDF file
BSByron Smith
Byron Smith
LCLynn D. Cornell
Lynn D. Cornell
MSMaxwell Smith
Maxwell Smith
CCCherise Cortese
Cherise Cortese
XGXochiquetzal Geiger
Xochiquetzal Geiger
MSMark Stegall
Mark Stegall
Poor reproducibility in scoring antibody‐mediated rejection (ABMR) using the Banff criteria might limit the use of histology in clinical trials. We evaluated the reproducibility of Banff scoring of 67 biopsies by six renal pathologists at three institutions. Agreement by any two pathologists was poor: 44.8–65.7% for glomerulitis, 44.8–67.2% for peritubular capillaritis, and 53.7–80.6% for chronic glomerulopathy (cg). All pathologists agreed on cg0 (n = 20) and cg3 (n = 9) cases, however, many disagreed on scores of cg1 or cg2. The range for the incidence of composite diagnoses by individual pathologists was: 16.4–22.4% for no ABMR; 17.9–47.8% for active ABMR; and 35.8–59.7% for chronic, active antibody‐mediated rejection (cABMR). A “majority rules” approach was then tested in which the scores of three pathologists were used to reach an agreement. This increased consensus both for individual scores (ex. 67.2–77.6% for cg) and for composite diagnoses (ex. 74.6–86.6% cABMR). Modeling using these results showed that differences in individual scoring could affect the outcome assessment in a mock study of cABMR. We conclude that the Banff schema has high variability and a majority rules approach could be used to adjudicate differences between pathologists and reduce variability in scoring in clinical trials.

4 April 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ADAleksandar Denic
Aleksandar Denic
MMMartha C. Morales
Martha C. Morales
WPWalter D. Park
Walter D. Park
BSByron H. Smith
Byron H. Smith
WKWalter K. Kremers
Walter K. Kremers
MSMark D. Stegall
Mark D. Stegall
The current Banff scoring system was not developed to predict graft loss and may not be ideal for use in clinical trials aimed at improving allograft survival. We hypothesized that scoring histologic features of digitized renal allograft biopsies using a continuous, more objective, computer-assisted morphometric (CAM) system might be more predictive of graft loss. We performed a nested case-control study in kidney transplant recipients with a surveillance biopsy obtained 5 years after transplantation. Patients that developed death-censored graft loss (n = 67) were 2:1 matched on age, gender, and follow-up time to controls with surviving grafts (n = 134). The risk of graft loss was compared between CAM-based models vs a model based on Banff scores. Both Banff and CAM identified chronic lesions associated with graft loss (chronic glomerulopathy, arteriolar hyalinosis, and mesangial expansion). However, the CAM-based models predicted graft loss better than the Banff-based model, both overall (c-statistic 0.754 vs 0.705, P < .001), and in biopsies without chronic glomerulopathy (c-statistic 0.738 vs 0.661, P < .001) where it identified more features predictive of graft loss (% luminal stenosis and % mesangial expansion). Using 5-year renal allograft surveillance biopsies, CAM-based models predict graft loss better than Banff models and might be developed into biomarkers for future clinical trials.

8 February 2024 in Kidney360
Verified
Journal Article
Open access
MMMartha Catalina Morales-Alvarez
Martha Catalina Morales-Alvarez
VNVoravech Nissaisorakarn
Voravech Nissaisorakarn
LALawrence Appel
Lawrence Appel
E3EDGAR MILLER 3rd
EDGAR MILLER 3rd
RCRobert H. Christenson
Robert H. Christenson
SJStephen P. Juraschek
Stephen P. Juraschek
Key Points: Sodium reduction over a 4-week period decreased eGFR. Combining sodium reduction with the Dietary Approaches to Stop Hypertension diet resulted in larger reductions in eGFR. Changes in diastolic BP seem partially responsible for the observed dietary effects. Background: A potassium-rich Dietary Approaches to Stop Hypertension (DASH) diet combined with low sodium reduces BP. However, the effects of sodium reduction in combination with the DASH diet on kidney function are unknown. We determined the effects of sodium reduction and the DASH diet, on eGFR using cystatin C. Methods: DASH-sodium was a controlled, feeding study in adults with elevated or stage 1 hypertension, randomly assigned to the DASH or a control diet. On their assigned diet, participants consumed each of three sodium levels for 30 days after a 2-week run-in period of a high sodium-control diet. The three sodium levels were low (50 mmol/d), medium (100 mmol/d), and high (150 mmol/d). The primary outcome was change in eGFR based on cystatin C. Results: Cystatin C was measured in 409 of the original 412 participants, of which 207 were assigned the DASH diet and 202 to the control diet. Compared with control, the DASH diet did not affect eGFR (β=−0.96 ml/min per 1.73 m2; 95% confidence interval [CI], −2.74 to 0.83). By contrast, low versus high sodium intake decreased eGFR (β=−2.36 ml/min per 1.73 m2; 95% CI, −3.64 to −1.07). Together, compared with the high sodium-control diet, the low sodium-DASH diet decreased eGFR by 3.10 ml/min per 1.73 m2 (95% CI, −5.46 to −0.73). This effect was attenuated with adjustment for diastolic BP and 24-hour urinary potassium excretion. Conclusions: A combined low sodium-DASH diet reduced eGFR over a 4-week period. Future research should focus on the effect of these dietary interventions on subclinical kidney injury and their long-term effect on progression to CKD. Clinical Trial registration number: ClinicalTrials.gov, NCT00000608.

1 January 2017 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
MPMaria Camila Pérez-Matos
Maria Camila Pérez-Matos
MMMartha Catalina Morales-Álvarez
Martha Catalina Morales-Álvarez
FTFreddy Jean Karlo Toloza
Freddy Jean Karlo Toloza
MRMaria Laura Ricardo-Silgado
Maria Laura Ricardo-Silgado
JMJose Oscar Mantilla-Rivas
Jose Oscar Mantilla-Rivas
CMCarlos O Mendivil
Carlos O Mendivil
Pérez-Matos MC, et al. Diabetes Metab J. 2017 Dec;41(6):466-473. https://doi.org/10.4093/dmj.2017.41.6.466